ArticleTherapeutic advances in gastroenterology2022
Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial.
Article in Therapeutic advances in gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02421627 (Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome), which is not on this map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Visualization analysis of research hotspots and trends in traditional Chinese medicine external therapies for irritable bowel syndrome.Frontiers in medicine · 2026Pooled it
- Placebo setting in trials of traditional Chinese medicine nursing techniques: a systematic critical reviewBMC complementary medicine and therapies · 2025Pooled it
- Acupuncture and related therapies for the anxiety and depression in irritable bowel syndrome with diarrhea (IBS-D): A network meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2022Pooled it
- Clinical evidence of acupuncture and moxibustion for irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.Frontiers in public health · 2022Pooled it
- The Potential of Complementary and Alternative Therapies in Improving Diarrhea-Predominant Irritable Bowel Syndrome: Strategies for Long-Term Efficacy.Digestive diseases and sciences · 2026Review
- Effect of Du-Moxibustion Combined With Spine-Pinching Therapy on Cognitive Frailty in Older Adults With Prefrailty: Protocol for a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Herbal hot compress combined with bianstone warm ironing improves anxiety and cognitive impairment via gut-brain-HPA axis in pubertal mesenteric lymphadenitis rats.Frontiers in pediatrics · 2026Article
- Gui-Shao San Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome With Liver Depression and Spleen Deficiency Pattern: A Randomized Controlled Trial.Gastroenterology research and practice · 2026Article
- Effects of acupuncture versus moxibustion on functional dyspepsia: a randomized clinical trial.Chinese medicine · 2025Article
- Moxibustion ameliorates chronic inflammatory visceral pain via spinal circRNA-miRNA-mRNA networks: a central mechanism study.Molecular brain · 2024Article
- Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome.World journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMoxibustion is increasingly used for treatment of irritable bowel syndrome (IBS). This study investigated the long-term effects of moxibustion for IBS with diarrhea (IBS-D).
methodsPatients with IBS-D were assigned to receive moxibustion or sham moxibustion (52 each, 3× per week, 6 weeks) and were followed up to 24 weeks. The acupoints were bilateral ST25 and ST36, body surface temperatures at acupoints were 43°C ± 1°C and 37°C ± 1°C for the moxibustion and sham groups, respectively. Primary outcome was changes in IBS Adequate Relief (IBS-AR) from baseline to 6 weeks. Secondary outcomes included the following: IBS symptom severity scale (IBS-SSS), Bristol stool form scale (BSS), IBS quality of life (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS).
resultsBased on an intention-to-treat analysis, the rate of IBS-AR in the moxibustion group was significantly higher than the sham group at 6 weeks (76.9%
conclusionsMoxibustion treatment benefits the long-term relief of symptoms in IBS-D patients.
trial registrationClinical trials.gov (NCT02421627). Registered on 20 April 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.